Alpha-2 adrenoceptor agonists and sepsis: improved survival? by Quintin, Luc
Dr Pandharipande and colleagues should be com-
mended for segregating the eﬀ  ect of dexmedetomidine, 
an alpha-2 adrenoceptor agonist, in sepsis [1]. However, 
three questions arise from their study: what are the P-
values for the data reported in Table 1? Why was there 
such a discrepancy between the fentanyl dose given to 
patients on dexmedetomidine and those on lorazepam 
(1,114 versus 117 μg/day, P = 0.01) considering the 50 to 
80% reduction in the use of opiates commonly observed 
in the literature when alpha-2 adrenoceptor agonists are 
administered? And how many days did the patients spend 
on spontaneous (for example, pressure support) versus 
controlled/assisted ventilation?
In their study, survival was better (a 70% reduction in 
risk of dying at 28 days) in patients on dexmedetomidine 
(n = 31) than in those on lorazepam (n = 32). Improved 
survival was observed earlier in tetanus patients [2] (rate 
of death of 50% versus 11% in control (n = 10) versus 
clonidine-treated (n = 17) patients; P = 0.04; this 1998 
reference is not cited in the bibliography). In the study of 
Dr Pandharipande and colleagues, baseline charac  teristics 
were slightly diﬀ  erent (Table 1 in [1]): tempera  ture, heart/
respiratory rate, incidence of vaso  pressors (dex-
medetomidine, 32%; lorazepam, 56%) and drotre  co  gin 
alpha (activated; P = 0.20) were higher and systolic 
pressure lower in the lorazepam group despite ‘similar 
severity of illness’. Could bias explain partially improved 
survival? As concluded by the authors [1], a larger trial 
should demonstrate improved survival (for example, 
upon septic shock [3]).
Secondly, the dexmedetomidine patients received ten 
times more fentanyl and had more ventilator-free days. 
Usually, alpha-2 adrenoceptor agonists reduce the need 
for opiates by 50 to 80% and preserve spontaneous 
ventilation. So why this discrepancy?
Th   irdly, vasopressor requirements were reduced in the 
dexmedetomidine group (Table 3 in [1]). A 2003 refer-
ence [4] showed previously a reduced vasopressor 
require  ment and was not cited in the bibliography. Could 
more ventilator-free days lead to less infections [5,6], 
improved survival, lowered intra  thoracic pressure and 
reduced vasopressor requirements?
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Dr Quintin raises interesting questions regarding our 
analyses of the septic subgroup in the MENDS trial [7], 
which found improved outcomes and survival in septic 
patients treated with dexmedetomidine versus 
lorazepam [1]. In Table 1, we did not report P-values to 
avoid mis  leading readers into believing the groups were 
perfectly balanced. Indeed, we advised caution when 
interpreting these results since subgroup analyses are 
prone to type II errors; that is, due to the reduced sample 
sizes, some imbalances could have occurred that - 
though not statis  tically signiﬁ   cant - could have been 
clinically important. We attempted, therefore, to reduce 
the impact of potential imbalances by adjusting for age, 
severity of illness and use of drotrecogin alfa.
Fentanyl was used both as an analgesic and supple-
mental sedative when a deeper level of sedation (than 
that achieved with the study drug) was ordered by the 
medical team. Higher doses of fentanyl were noted in 
the dexmedetomidine group primarily when patients 
were deeply sedated [7], suggesting the increased 
fentanyl use reﬂ   ected a need for additional sedation 
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© 2010 BioMed Central Ltdrather than analgesia. Previous studies reporting opioid-
sparing eﬀ   ects of dexmedetomidine have examined 
intraopera  tive use [8] or short-term use after surgery [9], 
both of which involve diﬀ   erent populations than that 
studied in MENDS.
We did not evaluate modes of ventilation. We did ﬁ  nd 
an increase in ventilator-free days in septic patients 
sedated with dexmedetomidine versus lorazepam, but 
did not ﬁ  nd a reduction in secondary infections as seen 
in SEDCOM [6]. Th  us, our results do not support the 
hypothesis that a reduced ventilator time in the septic 
dexmedetomidine group resulted in lower secondary 
infections and thereby improved survival.
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